According to a clinical research plan updated by the company in early 2024, Lilly will conduct multiple Phase 3 clinical trials for Retatrutide over the next three years, with targeted indications primarily including obesity, chronic kidney disease, and type 2 diabetes
Retatrutide affects gastric emptying, potentially altering absorption of oral medications
The upper body is not affected (except for arms in some types), so the size of the lower body is disproportionate and the body shape is distorted
In preclinical research environments, the individual components of KLOW Blend have been studied for their interaction with cellular communication networks, cytoskeletal regulation, inflammatory signaling pathways, extracellular matrix organization, and copper-dependent biochemical signaling systems
Rare but serious side effects ( 10%), including nausea, constipation or diarrhea, loss of appetite/feeling of fullness, and acid reflux